Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

MATTHIJS DE LIGT claims Erik ten Hag was “unlucky” to be sacked by Manchester United and reckons his side “played well in many matches.” De Ligt, 25, joined United from Bayern Munich in ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. After a rejection in July, drug reviewers at the EMA have now ...

Nov 14 (Reuters) - The European Union's drugs regulator on Thursday recommended approval of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi for some patients with early ...

You can check out at any time. More info Manchester United centre-back Matthijs de Ligt has suggested Erik ten Hag didn't get the breaks he needed to keep his job at Old Trafford despite the ...

Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai ...

Matthijs de Ligt heeft een wat wrang gevoel overgehouden aan het ontslag van trainer Erik ten Hag bij Manchester United. De verdediger kreeg eind oktober in de uitwedstrijd tegen West Ham United ...

LONDON — Reversing an earlier decision, European regulators on Thursday recommended that an Alzheimer’s therapy from Eisai and Biogen should be approved, saying that the benefits of the ...

The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...

Artist and craftsman, proto-installation artist, grandmaster of striking stagings, and one of Auguste Rodin’s competitors—Medardo Rosso numbered among the great trailblazers of modernity.

Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease amyotrophic lateral sclerosis that could have been worth up to $217 ...

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.